BCYC logo

BCYC
Bicycle Therapeutics Plc - ADR

931
Mkt Cap
$246.65M
Volume
693,128.00
52W High
$9.55
52W Low
$4.24
PE Ratio
-1.56
BCYC Fundamentals
Price
$4.94
Prev Close
$4.97
Open
$4.97
50D MA
$5.24
Beta
1.23
Avg. Volume
546,855.62
EPS (Annual)
-$3.17
P/B
0.56
Rev/Employee
$252,623.69
$120.63
Loading...
Loading...
News
all
press releases
Morgan Stanley Has Lowered Expectations for Bicycle Therapeutics (NASDAQ:BCYC) Stock Price
Morgan Stanley lowered their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an "equal weight" rating for the company in a report on Wednesday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $29,297.97 in Stock
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold...
MarketBeat·6d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the firm's stock in a transaction on Thursday, April 2nd. The shares were sold at an average...
MarketBeat·6d ago
News Placeholder
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has received a consensus rating of "Hold" from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold...
MarketBeat·8d ago
News Placeholder
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·20d ago
News Placeholder
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·21d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Bicycle Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·23d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Price Target Lowered to $36.00 at Oppenheimer
Oppenheimer decreased their target price on shares of Bicycle Therapeutics from $44.00 to $36.00 and set an "outperform" rating for the company in a research note on Wednesday...
MarketBeat·25d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Given New $7.00 Price Target at Royal Bank Of Canada
Royal Bank Of Canada reduced their target price on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a "sector perform" rating for the company in a report on Wednesday...
MarketBeat·26d ago
News Placeholder
Bicycle Therapeutics (NASDAQ:BCYC) Price Target Cut to $8.00 by Analysts at Citizens Jmp
Citizens Jmp reduced their price target on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Wednesday...
MarketBeat·26d ago
<
1
2
...
>

Latest BCYC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.